Stockreport

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) [Yahoo! Finance]

Catalent, Inc.  (CTLT) 
Last catalent, inc. earnings: 2/3 07:30 am Check Earnings Report
US:NYSE Investor Relations: investor.catalent.com
PDF MindMed has announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) fo [Read more]